GLP-1 SV

Survodutide is a synthetic 29-amino acid peptide designed as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR).

Engineered with a C18 fatty diacid chain for albumin binding, it achieves an extended half-life of 109–115 hours, allowing convenient once-weekly subcutaneous administration. The peptide demonstrates preferential GLP-1R activation (~8:1 ratio GLP-1R:GCGR) to maximize metabolic benefits while minimizing potential glucagon-related adverse effects.

Weight Loss: Up to 14.9% reduction; 40% of patients achieved >20% weight loss in Phase 2 trials
Dual Pathway Metabolism: Combined appetite suppression (GLP-1R) and increased energy expenditure (GCGR)
Glycemic Control: HbA1c reduction ~1.5%, comparable to semaglutide, with additional weight loss
Cardiometabolic Health: Lowered blood pressure, triglycerides, and other cardiovascular risk markers
Energy Expenditure: Increased basal metabolic rate and fatty acid oxidation
Lean Mass Preservation: Muscle mass maintained during significant weight loss
Liver Health: Reduced hepatic lipid content in MASH/NAFLD contexts
Dosing Convenience: True weekly administration due to extended half-life
Clinical Development: Currently in Phase 3 trials evaluating safety and efficacy

Rosenstock, J., et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity. The Lancet Diabetes & Endocrinology, 12(3), 161–173. DOI: 10.1016/S2213-8587(23)00356-X
Frías, J.P., et al. (2024). Biomarker-guided approach to select survodutide for clinical development. Diabetes, Obesity and Metabolism, 26(7), 2731–2741. DOI: 10.1111/dom.15619
Tsoukas, M.A., et al. (2024). Survodutide: Novel mechanism of action for obesity and type 2 diabetes. Annals of Medicine and Surgery, 86(5), 2756–2763. DOI: 10.1097/MS9.0000000000001898
le Roux, C.W., et al. (2024). Rationale and design of Phase 3 trials (SYNCHRONIZE-1 and -2). Obesity, 33(2), 278–289. DOI: 10.1002/oby.24150
Rosenstock, J., et al. (2023). Weekly survodutide improves glycemic control in T2DM: Phase 2 trial. The Lancet Diabetes & Endocrinology, 11(11), 800–811. DOI: 10.1016/S2213-8587(23)00244-9

$210.00

Per Unit

In stock